Bellerophon therapeutics announces results of interim analysis of phase 3 covinox study of inopulse® for the treatment of covid-19

Warren, n.j., nov. 23, 2020 (globe newswire) -- bellerophon therapeutics, inc. (nasdaq: blph) (“bellerophon” or the “company”), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary and infectious diseases, today announced that the independent data monitoring committee (dmc) has completed its pre-specified interim analysis from the first 100 patients randomized in the phase 3 covinox study of inopulse® for the treatment of covid-19.
BLPH Ratings Summary
BLPH Quant Ranking